Synagis Solution For Injection 100Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Synagis: Solution for injection (100mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

PALIVIZUMAB (pal i VI zu mab) is an antibody. It is used in infants and children to prevent severe cases of respiratory syncytial virus (RSV) infection. Children treated with this medicine may still get RSV but will not get as sick as if they were not treated at all. This medicine does not protect against other infections.

In-Depth Information

Synagis 100mg/ml Solution for Injection

NDC: 605744113
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved





Storage Information
Refrigerate (between 36 and 46 degrees F)
Store in original container
Discard unused portion. Do not store for later use.
Do not freeze
Synagis 100mg/ml Solution for Injection

Reported Side Effects for Synagis 100mg/ml Solution for Injection

Severe Allergy Incidence:
<0.1%*
Severity: SEVERE
Onset: RAPID
Antibody Formation Incidence:
0.5-1.5%*
Severity: MODERATE
Onset: DELAYED
Skin Rash Incidence:
0.9-12.0%*
Severity: MILD
Onset: EARLY
Skin Redness Incidence:
1.4%*
Severity: MODERATE
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
2.3-3.6%*
Severity: MODERATE
Onset: DELAYED
Injection Site Reaction Incidence:
2.3%*
Severity: MILD
Onset: RAPID
Rhinitis Incidence:
26.8%*
Severity: MILD
Onset: EARLY
Fever Incidence:
27.1%*
Severity: MILD
Onset: EARLY
Infection Incidence:
50.6%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Synagis

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.